Research Article
Iron Overload Impairs Bone Marrow Mesenchymal Stromal Cells from Higher-Risk MDS Patients by Regulating the ROS-Related Wnt/β-Catenin Pathway
Table 3
Next generation sequencing of the intermediate or high-risk MDS patients.
| | NIO MDS group (11) | IO MDS group (10) | value |
| | Presence of gene mutation | 8 (72.7%) | 10 (100%) | 0.214 | | STAG2 | 1 (9.1%) | 0 (0) | 1.000 | | BCOR | 1 (9.1%) | 0 (0) | 1.000 | | ASXL1 | 1 (9.1%) | 6 (60.0%) | 0.024 | | U2AF1 | 1 (9.1%) | 3 (30.0%) | 0.311 | | RUNX1 | 3 (27.3%) | 1 (10.0%) | 0.586 | | ZRSR2 | 1 (9.1%) | 0 (0) | 1.000 | | WT1 | 1 (9.1%) | 2 (20.0%) | 0.586 | | GATA2 | 1 (9.1%) | 3 (30.0%) | 0.311 | | TET2 | 2 (18.2%) | 7 (70.0%) | 0.030 | | TP53 | 1 (9.1%) | 0 (0) | 1.000 | | NRAS | 1 (9.1%) | 0 (0) | 1.000 | | SETBP1 | 1 (9.1%) | 1 (10.0%) | 1.000 | | DNMT3A | 1 (9.1%) | 0 (0) | 1.000 | | IDH | 0 (0) | 1 (10.0%) | 0.476 | | EZH2 | 0 (0) | 1 (10.0%) | 0.476 |
|
|
